Celularity (NASDAQ:CELU) Posts Earnings Results

Celularity (NASDAQ:CELU) released its quarterly earnings results on Tuesday. The company reported $0.02 earnings per share for the quarter, FiscalAI reports. The firm had revenue of $3.85 million during the quarter.

Celularity Stock Performance

CELU traded down $0.03 on Tuesday, reaching $1.37. The company had a trading volume of 39,538 shares, compared to its average volume of 1,436,795. Celularity has a 52-week low of $0.56 and a 52-week high of $2.55. The company has a market cap of $39.66 million, a price-to-earnings ratio of -0.41 and a beta of 0.79. The business has a 50 day simple moving average of $1.08 and a 200 day simple moving average of $1.01.

Hedge Funds Weigh In On Celularity

A hedge fund recently bought a new stake in Celularity stock. C V Starr & Co. Inc. acquired a new stake in shares of Celularity, Inc. (NASDAQ:CELU) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity comprises approximately 0.8% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 4th biggest position. C V Starr & Co. Inc. owned approximately 2.64% of Celularity as of its most recent SEC filing. 19.02% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Celularity Company Profile

Celularity, Inc is a biotechnology company developing allogeneic cell therapies and biomaterial products derived from human placenta. The company’s research focuses on using placental cells and tissues to address unmet needs in oncology, immune-mediated diseases and regenerative medicine.

Celularity’s therapeutic pipeline has included CYNK-001, an off-the-shelf natural killer cell therapy being investigated for certain blood cancers, as well as other engineered and unmodified placental-derived cell programs.